Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
- 1 April 2000
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (8), 637-643
- https://doi.org/10.1038/sj.gt.3301152
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 27 references indexed in Scilit:
- Immune responses to adenovirus and adeno-associated virus in humansGene Therapy, 1999
- Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluidGene Therapy, 1999
- Adenoviral vectors: not to be sneezed atGene Therapy, 1998
- Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expressionGene Therapy, 1997
- The Prognostic Implication of Ascites in Advanced-Stage Ovarian CancerGynecologic Oncology, 1996
- Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral VectorsHuman Gene Therapy, 1996
- “Sero-Switch” Adenovirus-MediatedIn VivoGene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus SerotypeHuman Gene Therapy, 1996
- MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenovirusesImmunity, 1994
- Malignancy-Related Ascites and Ascitic Fluid “Humoral Tests of Malignancy”Journal of Clinical Gastroenterology, 1994
- Vehicles for gene therapyNature, 1993